Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2015 Nov;33(11):1735-40.
doi: 10.1007/s00345-015-1542-3. Epub 2015 Mar 31.

Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS)

Hanna Vasarainen  1 , Jolanda Salman  2 , Heidi Salminen  3 , Riccardo Valdagni  4 , Tom Pickles  5 , Chris Bangma  2 , Monique J Roobol  2 , Antti Rannikko  3
Affiliations
Multicenter Study

Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS)

Hanna Vasarainen et al. World J Urol. 2015 Nov.

Abstract

Purpose: To evaluate the utility of percentage of free serum PSA (%fPSA) as a predictor of adverse rebiopsy findings, treatment change and radical prostatectomy (RP) findings in a prospective active surveillance (AS) trial.

Methods: Patients enrolled in the global PRIAS study with baseline %fPSA available were included. Putative baseline predictors (e.g. PSA, %fPSA) of adverse rebiopsy findings were explored using logistic regression analysis. Association of variables with treatment change and RP findings over time were evaluated with Cox regression analysis. Active treatment-free survival was assessed with a Kaplan-Meier method.

Results: Of 3701 patients recruited to PRIAS, 939 had %fPSA measured at study entry. Four hundred and thirty-eight of them had %fPSA available after 1 year. Median follow-up was 17.2 months. First rebiopsy results were available for 595 patients and of those, 144 (24.2 %) had adverse findings. A total of 283 (30.1 %) patients discontinued surveillance, of those 181 (64.0 %) due to protocol-based reasons. Although median %fPSA values were significantly lower in patients who changed treatment, according to the multivariate regression analysis, initial %fPSA value was not predictive for treatment change or adverse rebiopsy findings. However, the probability of discontinuing AS was significantly lower in patients with "favourable" initial %fPSA characteristics and %fPSA during follow-up (initial %fPSA ≥15 and positive %fPSA velocity) compared to those with "adverse" %fPSA characteristics (initial %fPSA <15 and negative %fPSA velocity).

Conclusions: Diagnostic %fPSA provides no additional prognostic value when compared to other predictors already in use in AS protocols. However, %fPSA velocity during surveillance may aid in predicting the probability for future treatment change.

Keywords: Active surveillance; Free prostate-specific antigen; Prostate cancer; Prostate-specific antigen.

PubMed Disclaimer

References

    1. J Clin Oncol. 2011 Jun 1;29(16):2185-90 - PubMed
    1. J Urol. 2014 Mar;191(3):629-37 - PubMed
    1. JAMA. 1995 Oct 18;274(15):1214-20 - PubMed
    1. Urology. 2000 Aug 1;56(2):255-60 - PubMed
    1. Eur Urol. 2007 Dec;52(6):1560-3 - PubMed

Publication types

Substances

LinkOut - more resources